The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts
Priya Muthu
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Search for more papers by this authorKatarzyna Kazmierczak
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Search for more papers by this authorMichelle Jones
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Search for more papers by this authorCorresponding Author
Danuta Szczesna-Cordary
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Danuta SZCZESNA-CORDARY, Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, 1600 NW, 10th Avenue, RMSB 6113 (R-189), Miami, FL 33136, USA. Tel.: +1-(305)-243-2908 Fax: +1-(305)-243-4555 E-mail: [email protected]Search for more papers by this authorPriya Muthu
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Search for more papers by this authorKatarzyna Kazmierczak
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Search for more papers by this authorMichelle Jones
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Search for more papers by this authorCorresponding Author
Danuta Szczesna-Cordary
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
Danuta SZCZESNA-CORDARY, Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, 1600 NW, 10th Avenue, RMSB 6113 (R-189), Miami, FL 33136, USA. Tel.: +1-(305)-243-2908 Fax: +1-(305)-243-4555 E-mail: [email protected]Search for more papers by this authorAbstract
Phosphorylation of the myosin regulatory light chain (RLC) by Ca2+-calmodulin–activated myosin light chain kinase (MLCK) is known to be essential for the inotropic function of the heart. In this study, we have examined the effects of MLCK-phosphorylation of transgenic (Tg) mouse cardiac muscle preparations expressing the D166V (aspartic acid to valine)–RLC mutation, identified to cause familial hypertrophic cardiomyopathy with malignant outcomes. Our previous work with Tg-D166V mice demonstrated a large increase in the Ca2+ sensitivity of contraction, reduced maximal ATPase and force and a decreased level of endogenous RLC phosphorylation. Based on studies demonstrating the beneficial and/or protective effects of cardiac myosin phosphorylation for heart function, we hypothesized that an ex vivo phosphorylation of Tg-D166V cardiac muscle may rescue the detrimental contractile phenotypes observed earlier at the level of single myosin molecules and in Tg-D166V papillary muscle fibres. We showed that MLCK-induced phosphorylation of Tg-D166V cardiac myofibrils and muscle fibres was able to increase the reduced myofibrillar ATPase and reverse an abnormally increased Ca2+ sensitivity of force to the level observed for Tg-wild-type (WT) muscle. However, in contrast to Tg-WT, which displayed a phosphorylation-induced increase in steady-state force, the maximal tension in Tg-D166V papillary muscle fibres decreased upon phosphorylation. With the exception of force generation data, our results support the notion that RLC phosphorylation works as a rescue mechanism alleviating detrimental functional effects of a disease causing mutation. Further studies are necessary to elucidate the mechanism of this unexpected phosphorylation-induced decrease in maximal tension in Tg-D166V–skinned muscle fibres.
References
- 1 Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008; 19: 104–10.
- 2 Szczesna D. Regulatory light chains of striated muscle myosin. Structure, function and malfunction. Curr Drug Targets Cardiovasc Haematol Disord. 2003; 3: 187–97.
- 3 Poetter K, Jiang H, Hassanzadeh S, et al . Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996; 13: 63–9.
- 4 Richard P, Charron P, Carrier L, et al . Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107: 2227–32.
- 5 Andersen PS, Havndrup O, Bundgaard H, et al . Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations. J Med Genet. 2001; 38: E43.
- 6 Flavigny J, Richard P, Isnard R, et al . Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med. 1998; 76: 208–14.
- 7 Morner S, Richard P, Kazzam E, et al . Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. J Mol Cell Card. 2003; 35: 841–9.
- 8 Richard P, Charron P, Carrier L, et al . Correction to: “Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy”. Circulation. 2004; 109: 3258.
- 9 Brown JH, Kumar VS, O'Neall-Hennessey E, et al . Visualizing key hinges and a potential major source of compliance in the lever arm of myosin. Proc Natl Acad Sci USA. 2011; 108: 114–9.
- 10 Rayment I, Rypniewski WR, Schmidt-Base K, et al . Three-dimensional structure of myosin subfragment-1: a molecular motor. Science. 1993; 261: 50–8.
- 11 Kerrick WGL, Kazmierczak K, Xu Y, et al . Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice. FASEB J. 2009; 23: 855–65.
- 12 Muthu P, Mettikolla P, Calander N, et al . Single molecule kinetics in the familial hypertrophic cardiomyopathy D166V mutant mouse heart. J Mol Cell Cardiol. 2010; 48: 989–98.
- 13 Sweeney HL, Bowman BF, Stull JT. Myosin light chain phosphorylation in vertebrate striated muscle: regulation and function. Am J Physiol. 1993; 264: C1085–95.
- 14 Morano I. Tuning the human heart molecular motors by myosin light chains. J Mol Med. 1999; 77: 544–55.
- 15 Huang J, Shelton JM, Richardson JA, et al . Myosin regulatory light chain phosphorylation attenuates cardiac hypertrophy. J Biol Chem. 2008; 283: 19748–56.
- 16 Abraham TP, Jones M, Kazmierczak K, et al . Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice. Cardiovasc Res. 2009; 82: 84–92.
- 17 Greenberg MJ, Mealy TR, Watt JD, et al . The molecular effects of skeletal muscle myosin regulatory light chain phosphorylation. Am J Physiol Regul Integr Comp Physiol. 2009; 297: R265–74.
- 18 Dweck D, Reyes-Alfonso A Jr, Potter JD. Expanding the range of free calcium regulation in biological solutions. Anal Biochem. 2005; 347: 303–15.
- 19 Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem. 1925; 66: 375–400.
- 20 Szczesna-Cordary D, Guzman G, Zhao J, et al . The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice. J Cell Sci. 2005; 118: 3675–83.
- 21 Hill TL, Einsenberg E, Greene LE. Theoretical model for the cooperative equilibrium binding of myosin subfragment-1 to the actin-troponin-tropomyosin complex. Proc Natl Acad Sci. 1980; 77: 3186–90.
- 22 Szczesna D, Ghosh D, Li Q, et al . Familial hypertrophic cardiomyopathy mutations in the regulatory light chains of myosin affect their structure, Ca2+ binding, and phosphorylation. J Biol Chem. 2001; 276: 7086–92.
- 23 Szczesna D, Zhao J, Jones M, et al . Phosphorylation of the regulatory light chains of myosin affects Ca2+ sensitivity of skeletal muscle contraction. J Appl Physiol. 2002; 92: 1661–70.
- 24 Davis JS, Hassanzadeh S, Winitsky S, et al . The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell. 2001; 107: 631–41.
- 25 Wang Y, Xu Y, Kerrick WGL, et al . Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations. J Mol Biol. 2006; 361: 286–99.
- 26 Ding P, Huang J, Battiprolu PK, et al . Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. J Biol Chem. 2010; 285: 40819–29.
- 27 Olsson MC, Patel JR, Fitzsimons DP, et al . Basal myosin light chain phosphorylation is a determinant of Ca2+ sensitivity of force and activation dependence of the kinetics of myocardial force development. Am J Physiol Heart Circ Physiol. 2004; 287: H2712–8.
- 28 Palmer BM, Moore RL. Myosin light chain phosphorylation and tension potentiation in mouse skeletal muscle. Am J Physiol. 1989; 257: C1012–9.
- 29 Davis JS, Satorius CL, Epstein ND. Kinetic effects of myosin regulatory light chain phosphorylation on skeletal muscle contraction. Biophys J. 2002; 83: 359–70.
- 30 Ryder JW, Lau KS, Kamm KE, et al . Enhanced skeletal muscle contraction with myosin light chain phosphorylation by a calmodulin-sensing kinase. J Biol Chem. 2007; 282: 20447–54.
- 31 Zhi G, Ryder JW, Huang J, et al . Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. PNAS. 2005; 102: 17519–24.
- 32 Greenberg MJ, Kazmierczak K, Szczesna-Cordary D, et al . Cardiomyopathy-linked myosin regulatory light chain mutations disrupt myosin strain-dependent biochemistry. Proc Natl Acad Sci U S A. 2010; 107: 17403–8.
- 33 Greenberg MJ, Watt JD, Jones M, et al . Regulatory light chain mutations associated with cardiomyopathy affect myosin mechanics and kinetics. J Mol Cell Cardiol. 2009; 46: 108–15.
- 34 van der Velden J, Papp Z, Boontje NM, et al . Myosin light chain composition in non-failing donor and end-stage failing human ventricular myocardium. Adv Exp Med Biol. 2003; 538: 3–15.
- 35 van der Velden J, Papp Z, Boontje NM, et al . The effect of myosin light chain 2 dephosphorylation on Ca2+-sensitivity of force is enhanced in failing human hearts. Cardiovascular Research. 2003; 57: 505–14.
- 36 van der Velden J, Papp Z, Zaremba R, et al . Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res. 2003; 57: 37–47.
- 37 Colson BA, Locher MR, Bekyarova T, et al . Differential roles of regulatory light chain and myosin binding protein-C phosphorylations in the modulation of cardiac force development. J Physiol. 2010; 588: 981–93.
- 38 Levine RJ, Yang Z, Epstein ND, et al . Structural and functional responses of mammalian thick filaments to alterations in myosin regulatory light chains. J Struct Biol. 1998; 122: 149–61.
- 39 Stewart MA, Franks-Skiba K, Chen S, et al . Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers. Proc Natl Acad Sci U S A. 2010; 107: 430–5.
- 40 Hooijman P, Stewart MA, Cooke R. A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart. Biophys J. 2011; 100: 1969–76.
- 41 Vemuri R, Lankford EB, Poetter K, et al . The stretch-activation response may be critical to the proper functioning of the mammalian heart. Proc Natl Acad Sci U S A. 1999; 96: 1048–53.
- 42 Stelzer JE, Patel JR, Moss RL. Acceleration of stretch activation in murine myocardium due to phosphorylation of myosin regulatory light chain. J Gen Physiol. 2006; 128: 261–72.
Citing Literature
